Tech Company Financing Transactions
ProLynx Funding Round
5AM Ventures, Monograph Capital and OrbiMed joined a $70 million Series A capital raise for ProLynx. The round was announced on 12/11/2025.
Transaction Overview
Company Name
Announced On
12/11/2025
Transaction Type
Venture Equity
Amount
$70,000,000
Round
Series A
Investors
Proceeds Purpose
The company will use that cash to advance a portfolio of longer-acting "incretin" drugs -- which stimulate or mimic the effects of certain gut hormones -- as well as "non-incretin" therapies.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
135 Mississippi Street
San Francisco, CA 94107
USA
San Francisco, CA 94107
USA
Phone
Undisclosed
Website
Email Address
Overview
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and related metabolic diseases. The company's proprietary portfolio is built on a proven half-life extension technology engineered to support more consistent, long-term treatment with improved tolerability and optimized pharmacokinetics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chris Boulton
Browse more venture capital transactions:
Prev: 12/10/2025: Sprouty venture capital transaction
Next: 12/11/2025: Avedian venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs